DIVI'S LABORATORIES LTD.

NSE : DIVISLABBSE : 532488ISIN CODE : INE361B01024Industry : Pharmaceuticals & DrugsHouse : Divis Labs
BSE3764.75100.9 (+2.75 %)
PREV CLOSE ( ) 3663.85
OPEN PRICE ( ) 3671.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4098
TODAY'S LOW / HIGH ( )3671.05 3784.00
52 WK LOW / HIGH ( )2730 3949
NSE3765.15100.15 (+2.73 %)
PREV CLOSE( ) 3665.00
OPEN PRICE ( ) 3687.00
BID PRICE (QTY) 3765.15 (173)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 296674
TODAY'S LOW / HIGH( ) 3687.00 3784.00
52 WK LOW / HIGH ( )2730 3934.7
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 12-10 1990
Management Info
Ramesh BV Nimmagadda - Chairman Murali K Divi - Managing Director
Registered Office

Address 1-72/23( P)/ Divis/303,Divi Towers, Cyber Hills,Gachibowli,
Hyderabad,
Telangana-500032

Phone 040 66966300

Email mail@divislabs.com

Website www.divislabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS
19Aug Divi's Laboratories informs about earn
Divi's Laboratories has informed that it submitted the transcript of the..
16Aug Divi's Laboratories informs about news
Divi's Laboratories has informed that it enclosed copies of newspapers p..
14Aug Divi's Laboratories reports 49% fall i
Divi's Laboratories has reported results for first quarter ended June 30..
23May Divi's Laboratories informs about secr
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure R..
22May Divi's Laboratories reports 64% fall i
Divi's Laboratories has reported results for fourth quarter (Q4) and yea..
Financials
Rs. in Millions
QTR Jun 23 ANNUAL 23
Net Profit345018081.5
Gross Profit 4780 23541
Operating Profit 571026966.9
Net Sales 1730076253
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 23159.10 (3.44%)
M.Cap (Rs. in Cr)49211.47
Dr. Reddy's Lab (BSE)
 5586.75 (2.97%)
M.Cap (Rs. in Cr)93178.48
Sanofi India (BSE)
 7206.50 (2.09%)
M.Cap (Rs. in Cr)16597.02
Alkem Laboratories (BSE)
 3607.65 (2.41%)
M.Cap (Rs. in Cr)43134.87
JB Chem & Pharma (BSE)
 1483.65 (5.79%)
M.Cap (Rs. in Cr)22989.97
Shareholding Pattern
PROMOTERS 51.93%
MUTUAL FUNDS/UTI 13.2%
NON-INSTITUTION 12.14%
FI/BANKS/INSURANCE 7.03%
GOVERNMENT 0%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075,9768009000, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.